• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by Aurora Cannabis Inc.

    2/14/25 4:34:39 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email
    F-X 1 d850650dfx.htm F-X F-X

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM F-X

     

     

    APPOINTMENT OF AGENT FOR SERVICE

    OF PROCESS AND UNDERTAKING

     

     

     

    A.   Name of issuer or person filing (“Filer”):    Aurora Cannabis Inc.

     

    B.  

    (1)   This is [check one]:

     

    ☒   an original filing for the Filer

     

    ☐   an amended filing for the Filer

     

    (2)   Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9) ☐

    C.   Identify the filing in conjunction with which this form is being filed:

     

      Name of Registrant:    Aurora Cannabis Inc.
      Form type:    F-10
      File Number (if known):    333-284958
      Filed by:    Aurora Cannabis Inc.
      Date Filed (if filed concurrently, so indicate):    February 14, 2025 (filed concurrently)
    D.  

    The Filer is incorporated or organized under the laws of British Columbia, Canada and has its principal place of business at:

     

    2207 90B Street SW

    Edmonton, Alberta, Canada

    T6X 1V8

    Telephone: 1 (855) 279-4652

    E.  

    The Filer designates and appoints Puglisi & Associates located at:

     

    850 Library Avenue

    Suite 204

    Newark, DE 19711

    Telephone: (302) 738-6680

     

    as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in:

     

    (a) any investigation or administrative proceeding conducted by the Commission; and

     

    (b) any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form F-10 on February 14, 2025 or any purchases or sales of any security in connection therewith. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that the service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

    F.  

    The Filer stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which this Form relates has ceased reporting under the Exchange Act.

     

    The Filer further undertakes to advise the Commission promptly of any change to the Agent’s name or address during the applicable period by amendment of this Form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

    G.   The Filer undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the Form F-10, the securities to which the Form F-10 relates and the transactions in such securities.

     

     

     


    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, this 14th day of February, 2025.

     

    Filer:     Aurora Cannabis Inc.
        By:   /s/ Miguel Martin
        Name:   Miguel Martin
        Title:   Chief Executive Officer and Executive Chairman


    This statement has been signed by the following person in the capacity and on the date indicated.

     

    Puglisi & Associates

    as Agent for Service of Process for

    Aurora Cannabis Inc.

    By:   /s/ Donald J. Puglisi
    Name:   Donald J. Puglisi
    Title:   Managing Director
    Dated:   February 14, 2025
    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

    NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets  EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

    2/11/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

    NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion. The Company intends to use the net proceeds from th

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 4:44:28 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 9:45:22 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 7:27:19 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Aurora Cannabis

    Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy

    1/27/26 9:29:20 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    TD Cowen initiated coverage on Aurora Cannabis

    TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

    12/11/24 10:35:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

    2/9/24 6:09:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    View All

    Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand

    NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated

    12/8/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Announces Distribution Partnership with Leafio Australia

    The collaboration will improve medical cannabis access and better serve patients across Australia NASDAQ | TSX: ACB EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfoli

    12/2/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 21, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2026 on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 4, 2026 TIME: 8:00 a.m. Eastern Time |

    1/21/26 4:35:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/23 11:28:04 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/22 3:54:29 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care